NBA Star Giannis Antetokounmpo Takes Stake in David Beckham’s IM8

The two-time NBA MVP has added his name to IM8’s fast-growing athlete roster, backing the supplement company as it pushes deeper into global expansion

David Beckham co-founded longevity supplement company IM8 has added another big-name pro athlete to its roster: basketball star Giannis Antetokounmpo.

The deal makes the two-time NBA MVP a global partner of IM8 and the latest athlete shareholder of Prenetics Global Limited, the parent company of IM8.

IM8 is known for two core products: Daily Ultimate Essentials, a supplement powder that acts as a multivitamin, probiotic and more all wrapped into one, and Daily Ultimate Longevity, a pill to promote healthy aging at the cellular level.

The brand has leaned into science-backed marketing, asserting itself as one of the most effective and safe supplement makers in the industry.

“I’m very careful about what I put in my body and what I put my name on,” said Antetokounmpo. “For me, taking care of my body isn’t just about basketball — it’s about how I live every day. When I started taking IM8, I noticed the difference and it quickly became part of my daily routine.”

“It’s something that helps support my energy, recovery, and overall health so I can be at my best, both on and off the court,” he added. “As I kept using it, I wanted to learn more about the people behind it. I spent time getting to know the team and saw how serious they are about the science, the ingredients, and building something real in health and performance.”

Since launching in December 2024, the brand has seen notable growth. Within 11 months, IM8 reached $100 million in annualized recurring revenue. Currently, the company has a substantial global reach, dispersing more than 22 million servings and hitting more than 750,000 customer purchases across 31 countries.

Through the partnership with Antetokounmpo, IM8 is hoping to amplify its global influence further, tapping into the NBA star’s over 35 million followers across his social platforms, with particular popularity in the U.S., Europe, Africa and Asia — markets that align directly with the brand’s targets for global expansion.

On top of that, Antetokounmpo’s audience of 18–34 year-olds is a key target for IM8, not to mention the NBA’s global influence, which provides a direct channel into markets the brand has not yet activated at scale, all while Prenetics is targeting $180 million to $200 million in IM8 revenue for fiscal year 2026.

“He represents everything IM8 stands for: relentless discipline, authenticity, and an unwillingness to cut corners,” said Prenetics CEO and IM8 co-founder, Danny Yeung. “The fact that he chose 100% equity over any cash compensation says more about his belief in what we’re building than any marketing campaign ever could. He’s not lending us his name. He’s investing in our future.”

Antetokounmpo joins other athletes who have invested in IM8 — in addition to Beckham, tennis star Aryna Sabalenka and Formula 1 competitor Ollie Bearman have stakes in IM8.

“The supplement industry has been waiting for a brand that earns trust at the highest level,” said Prenetics CEO and IM8 co-founder Danny Yeung. “We now have the conviction of the most respected athletes across four of the world’s biggest sports, not through cash endorsement fees, but through equity. That roster does not exist anywhere else in the industry.”

“Combined with approximately $164 million in total adjusted liquidity, zero debt, and a clear path to profitability, we believe we are very well positioned to scale IM8 into a generational consumer health brand and to reward every shareholder and partner building it with us,” he added.